#aflibercept — Public Fediverse posts

Samsung Biologics? No — Samchundang Pharm Reaches Landmark Settlement in Eylea Biosimilar Patent Dispute, Clearing Path for Global Commercialization

Samchundang Pharm (000250) has effectively resolved the global patent dispute surrounding its biosimilar of the macular degeneration treatment…
#EuropeSays #Korea #KR #SamsungBiologics #aflibercept #Bayer #EuropeanPatentOffice #Eylea #RegeneronPharmaceuticals #SamchundangPharm #Samsung #SCD411 #Vizempre
https://www.europesays.com/korea/122838/

https://www.europesays.com/ch-fr/179100/ DMLA : thérapie génique, œil bionique et biosimilaire — une maladie à l’aube d’une révolution thérapeutique #aflibercept #biosimilaire #DégénérescenceMaculaire #DMLA #Health #HorusPharma #ImplantSousRétinien #InnovationMédicale #macula #œilBionique #ophtalmologie #rétine #Santé #Suisse #ThérapieGénique

https://www.europesays.com/be-fr/143543/ DMLA : thérapie génique, œil bionique et biosimilaire — une maladie à l’aube d’une révolution thérapeutique #aflibercept #BE #BEFr #Belgique #Belgium #biosimilaire #DégénérescenceMaculaire #DMLA #Health #HorusPharma #ImplantSousRétinien #InnovationMédicale #macula #œilBionique #ophtalmologie #rétine #Santé #ThérapieGénique

Samsung Bioepis Launches OPUVIZ™ (Aflibercept) 40 mg/mL Vial Across Europe, to Treat Ophthalmic Conditions

OPUVIZ™ 40 mg/mL solution for injection in a vial, a biosimilar referencing Eylea (aflibercept), will be rolled out…
#Europe #EU #aflibercept #commercialization #injection #macularoedema #medicine #OPUVIZ #Patients #retinalhaemorrhage #SamsungBioepis #sideeffects #visualimpairment
https://www.europesays.com/europe/55291/

https://www.europesays.com/ie/473517/ EYLEA® (aflibercept) 114.3 mg/mL receives hospital pricing approval from HSE #aflibercept #AgeRelatedMacularDegeneration #Bayer #Éire #Eylea #Health #IE #Ireland

Aflibercept
More effective than bevacizumab
Curing wet AMD
Helping patients on their way
Successful drug trials

#aflibercept #amd #drugtrials #wetamd #cinquain #poetry

http://www.medicalnewstoday.com/articles/one-of-two-widely-used-macular-degeneration-drugs-outperforming-other-at-weaning-patients-off-treatment-at-one-year

Aflibercept
More effective than bevacizumab
Curing wet AMD
Helping patients on their way
Successful drug trials

#aflibercept #amd #drugtrials #wetamd #cinquain #poetry

http://www.medicalnewstoday.com/articles/one-of-two-widely-used-macular-degeneration-drugs-outperforming-other-at-weaning-patients-off-treatment-at-one-year